Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

NCT01212822 | Completed Phase 2 Results DMC

• 4 other identifiers: FER-GI-029NCI-2013-00603IRB#10-022P30CA006927
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 3

Brief Summary

This pilot phase II trial studies how well giving bevacizumab and combination chemotherapy together before surgery works in treating patients with locally advanced esophageal or stomach cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab and combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.

Conditions

Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Squamous Cell Carcinoma of the Esophagus; Stage IA Esophageal Cancer; Stage IA Gastric Cancer; Stage IB Esophageal Cancer; Stage IB Gastric Cancer; Stage IIA Esophageal Cancer; Stage IIA Gastric Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer

Outcome Measures

Primary Outcomes (1)

• Disease-free Survival

  To investigate 2 year disease free survival in pts with resectable esophageal and GE junction cancer treated with perioperative bevaciumab and FOLFOX

  2 years

Secondary Outcomes (3)

• Complete and Partial Response to Neoadjuvant Therapy Based on the Response Evaluation Criteria in Solid Tumors (RECIST)

  Up to 3 years

• Overall Survival

  4.5 years

• Progression Free Survival

  3 years

Other Outcomes (1)

• Change in Biomarker Levels

  Baseline up to day of surgery

Study Arms (1)

Treatment (bevacizumab, FOLFOX)

EXPERIMENTAL

NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab. ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Biological: bevacizumab; Drug: oxaliplatin; Drug: leucovorin calcium; Drug: fluorouracil; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis

Interventions

bevacizumab BIOLOGICAL

Given IV

Also known as: anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF

Treatment (bevacizumab, FOLFOX)

oxaliplatin DRUG

Given IV

Also known as: 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP

Treatment (bevacizumab, FOLFOX)

leucovorin calcium DRUG

Given IV

Also known as: CF, CFR, LV

Treatment (bevacizumab, FOLFOX)

fluorouracil DRUG

Given IV

Also known as: 5-fluorouracil, 5-Fluracil, 5-FU

Treatment (bevacizumab, FOLFOX)

therapeutic conventional surgery PROCEDURE

Undergo surgical resection

Treatment (bevacizumab, FOLFOX)

laboratory biomarker analysis OTHER

Correlative studies

Treatment (bevacizumab, FOLFOX)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have biopsy proven adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma of the esophagus, GE junction and/or gastric cardia
• Patients must have potentially resectable disease by the thoracic, minimally invasive or transhiatal approach
• No portion of the lesion may be within 5 cm of the cricopharyngeus
• Patient must be considered medically fit for surgery with average or below average risk
• T1-3 or T4 with local invasion confined to diaphragm, pleura or pericardium
• No myocardial infarction within 12 months of enrollment
• Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• White blood cells (WBC) \>= 3,500/mm\^3
• Platelet count \>= 100,000/mm\^3
• Serum creatinine (Cr) =\< 1.5 mg and/or creatinine clearance \>= 60 cc/min
• Bilirubin must be \< upper limit of normal (ULN) unless the patient has a chronic grade 1 bilirubin elevation due to Gilbert's disease or similar syndrome due to slow conjugation of bilirubin
• Alkaline phosphatase must be \< ULN
• Aspartate aminotransferase (AST) \& alanine aminotransferase (ALT) must be \< ULN
• Urine protein/creatinine (UPC) ratio of \< 1.0 or dipstick for protein of \< 2+, Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4) grade \< 2; patients with a UPC ratio \>= 1.0 or dipstick of 2+ must undergo a 24-hour urine collection and must demonstrate \< 1 gm of protein in order to participate
• Patients must give written informed consent and Health Insurance Portability and Accountability Act (HIPAA) consent

You may not qualify if:

• Patients with prior chemotherapy for any malignant disorder, thoracic radiotherapy or prior surgical resection of an esophageal tumor are ineligible
• Patients with biopsy-proven invasion of the tracheobronchial tree or tracheo-esophageal fistula are ineligible
• Patients with a history of a curatively treated malignancy must be disease-free for at least two years and have a survival prognosis that is greater than five years
• Eligible patients of reproductive potential (both sexes) must agree to use an accepted and effective method of contraceptive during study therapy and for at least 6 months after the completion of bevacizumab; women must not be pregnant or breast-feeding because the study drugs administered may cause harm to an unborn fetus or breastfeeding child; all females of childbearing potential must have a serum pregnancy test to rule out pregnancy within 7 days prior to registration
• Patients with a history of hypertension must measure \< 150/90 mmHg and be on a stable regimen of anti-hypertensive therapy; patients with a history of hypertension who have a blood pressure of 150/90 mmHg, or greater are not eligible; patients with a history of hypertension who have a blood pressure of \< 150/90 mmHg but are not on a stable regimen of anti-hypertensive therapy, are not eligible
• Any prior history of hypertensive crisis or hypertensive encephalopathy
• New York Association (NYHA) grade II or greater congestive heart failure
• Patients must not have a serious or non-healing wound, skin ulcers or unhealed bone fracture, or known human immunodeficiency virus (HIV) infection
• Patients with \>= grade 2 neuropathy are not eligible
• Patients must not have had significant traumatic injury within 28 days prior to randomization
• Patients with PT (INR) \> 1.5 are not eligible; the patient may not be receiving full-dose anticoagulation; prophylactic or full dose anticoagulation are permitted post-resection or for treatment of an intercurrent thrombotic event
• Patients with non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude any of the study therapy drugs are not eligible; specifically excluded are the following conditions: current symptomatic arrhythmia, symptomatic peripheral vascular disease
• Patients with a history of the following within 12 months of study entry are not eligible: arterial thromboembolic events, unstable angina
• Any history of stroke or transient ischemic attack
• Significant vascular disease (i.e. aortic dissection, aortic aneurysm)

Sponsors & Collaborators

• Fox Chase Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (3)

Case Western Reserve University

Cleveland, Ohio, 44106, United States

Location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111-2497, United States

Location

University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, 15232, United States

Location

MeSH Terms

Conditions

Adenocarcinoma Of Esophagus; Esophageal Squamous Cell Carcinoma; Esophageal Neoplasms; Stomach Neoplasms

Interventions

Bevacizumab; Oxaliplatin; Leucovorin; Fluorouracil

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Coordination Complexes; Organic Chemicals; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Coenzymes; Enzymes and Coenzymes; Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring

Results Point of Contact

• Title: Protocol Development Coordinator
• Organization: Fox Chase Cancer Center

ryan.romasko@fccc.edu

215-728-4097

Study Officials

• Crystal Denlinger

  Fox Chase Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2010
• First Posted: October 1, 2010
• Study Start: April 27, 2011
• Primary Completion: October 24, 2014
• Study Completion: January 3, 2018
• Last Updated: September 7, 2022
• Results First Posted: September 7, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)